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Abstract
In the inherited childhood neuromuscular disease spinal muscular atrophy (SMA), lower motor neuron death and severe
muscle weakness result from the reduction of the ubiquitously expressed protein survival of motor neuron (SMN). Although
SMA mice recapitulate many features of the human disease, it has remained unclear if their short lifespan and motor
weakness are primarily due to cell-autonomous defects in motor neurons. Using Hb9Cre as a driver, we selectively raised SMN
expression in motor neurons in conditional SMAD7 mice. Unlike a previous study that used choline acetyltransferase
(ChATCre+) as a driver on the same mice, and another report that used Hb9Cre as a driver on a different line of conditional
SMA mice, we found no improvement in survival, weight, motor behavior and presynaptic neurofilament accumulation.
However, like in ChATCre+ mice, we detected rescue of endplate size and mitigation of neuromuscular junction (NMJ)
denervation status. The rescue of endplate size occurred in the absence of an increase in myofiber size, suggesting endplate
size is determined by the motor neuron in these animals. Real time-PCR showed that the expression of spinal cord SMN
transcript was sharply reduced in Hb9Cre+ SMA mice relative to ChATCre+ SMA mice. This suggests that our lack of overall
phenotypic improvement is most likely due to an unexpectedly poor recombination efficiency driven by Hb9Cre.
Nonetheless, the low levels of SMN were sufficient to rescue two NMJ structural parameters indicating that these motor
neuron cell autonomous phenotypes are very sensitive to changes in motoneuronal SMN levels. Our results directly suggest
that even those therapeutic interventions with very modest effects in raising SMN in motor neurons may provide mitigation
of neuromuscular phenotypes in SMA patients.
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Introduction
Spinal muscular atrophy (SMA) is an often fatal, childhood
inherited neuromuscular disease caused by low levels of a
ubiquitous protein required for spliceosome assembly, survival of
motor neuron (SMN). Reduction of SMN leads to loss of lower
motor neurons, muscle denervation and atrophy. There is no
current treatment for SMA. Humans harbor two genes encoding
SMN, SMN1 and SMN2. In SMA patients SMN production is
drastically reduced by homozygous deletion/mutation of SMN1.
In such patients SMN is solely derived from SMN2. SMN2 is
essentially identical to SMN1 except for a CRT nucleotide change
that causes exon 7 skipping in the splicing of ,90% SMN2 RNA,
leading to the synthesis of an unstable, minimally functional
protein (SMND7). Only,10% of SMN2 transcripts code for a full-
length SMN protein and this reduced level is insufficient for motor
neuron survival. SMN2 can exist in multiple copies and SMA
disease severity correlates inversely with SMN2 copy number
(reviewed in [1,2]).
Mice only harbor one SMN gene, whose homozygous deletion
(Smn2/2) is embryonic lethal. Smn2/2 mice with two copies of
SMN2 (i.e. Smn2/2; SMN2+/+) die perinatally and show features
resembling the most severe human disease [3]. Addition of a
transgene encoding the cDNA for SMND7 to these mice (i.e.
Smn2/2; SMN2+/+; SMND7) improves survival to 14 days on
average. These animals, referred to as SMAD7 mice, still display a
severe SMA phenotype. Thus, among other features, they
demonstrate impaired motor behavior, inability to thrive and
gain weight, and structural and functional defects in their
neuromuscular junctions (NMJs) that include presynaptic accu-
mulation of neurofilaments (NF), smaller and immature postsyn-
aptic apparatus and diminished neurotransmission [4–8]. A
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selective vulnerability to denervation of specific, clinically relevant
muscles has also been reported for these animals [9]. SMAD7 mice
are the best characterized and the most widely used SMA model
mice in preclinical trials.
Although SMA mice recapitulate many features of the human
disease, it remains unclear if their short lifespan and SMA
phenotype are primarily due to cell-autonomous defects in motor
neurons. The general expectation in the field has been that
selective SMN reduction in motor neurons should mimic the
phenotype of the severe SMA model mice, and that conversely,
selective restoration of SMN in motor neurons should dramatically
rescue the phenotype of SMA model mice. These predictions have
not been entirely borne out by the experiments. Thus, Olig2-Cre-
driven conditional reduction of SMN in motor neuron precursors
yields central and NMJ phenotypes in these animals that are
present in the SMA mice, but the former animals have very mild
SMA with a surprisingly long lifespan [10]. To conditionally
restore SMN expression in motor neurons and other cells, mice
with inducible mutant Smn alleles that can be reverted to
functional, wild-type-like alleles after Cre recombination, were
generated independently by two groups. These are the hybrid
rescue allele, SmnRes [11] (Fig 1) and the Smn2B-neo allele [12].
Recently, choline acetyltransferase-(ChAT)-driven Cre was used to
restore SMN expression in motor neurons of SmnRes/Res mice in the
SMAD7 background [13], while Hb9-driven Cre was used to
restore SMN expression in motor neurons of the Smn2B-neo/2B-neo
SMA mice [14]. Mice rescued by both approaches showed
measurable improvements in weight, motor behavior, central and
neuromuscular phenotypes relative to diseased controls, but
displayed a very modest increase in survival (8 and 5 days over
diseased controls, respectively). These latter results contrast with
the dramatic improvements, particularly in lifespan, produced by
pan-neuronal expression of SMN in Smn2/2; SMN2+/+ mice (210
days) [15], or in SMAD7 mice treated with CNS or peripherally-
directed viral vectors expressing SMN (50–200 days) [16,17], or
CNS and peripherally-delivered oligonucleotides that correct the
exon skipping defects in SMN2 (.100 days) [18,19].
Here we report on our attempt to restore SMN selectively in
motor neurons of SmnRes/Res SMAD7 mice with the same Hb9-Cre
driver used to rescue Smn2B-neo/2B-neo SMA mice. We found no
improvement in survival, motor behavior, presynaptic NF
accumulation and a marginal weight increase in our
Hb9(Cre+)SMA mice relative to Hb9(Cre2)SMA mice. However,
we detected rescue of endplate size and significant mitigation of
NMJ denervation status in Hb9Cre+ SMA mice. The rescue of
endplate size was not a consequence of an increase in myofiber
size. This pattern of mitigated peripheral structural phenotypes in
Hb9Cre+ SMA mice is similar to that in Myf5Cre+ SMA mice [13],
although the latter had restored SMN both in skeletal muscle and
spinal cord, thus suggesting that this rescue in the Myf5Cre+ SMA
mice is due to neuronal and not muscle SMN restoration.
Quantitative real time-polymerase chain reaction (qRT-PCR)
showed that expression of the repaired SmnRes allele (SMN67m8h,
Fig 1) was approximately 100-fold lower in spinal cord in our
Hb9Cre+ SMA mice than in the spinal cord from ChATCre+ SMA
mice. This suggests that our lack of overall phenotypic improve-
ment is most likely due to an unexpectedly poor recombination
efficiency driven by Hb9Cre. Nonetheless, our data show that
specific structural NMJ phenotypes are very sensitive to small
changes in SMN levels selectively in motor neurons and thus can
be mitigated by very small increases in spinal cord SMN levels that
otherwise fail at enhancing lifespan, weight and motor behavior.
Although prior studies (e.g. [9,20,21]) have suggested that
therapeutic interventions with very modest effects in raising
SMN could potentially mitigate motor neuron-autonomous
phenotypes in SMA patients, our results are the first to reach
that conclusion directly based on an approach to selectively raise
SMN levels in motor neurons.
Figure 1. Schematic representation of the Smn WT allele and the SmnRes conditional hybrid mutant allele before and after Hb9-Cre
recombination. Blue boxes represent mouse Smn exons. Red boxes represent human SMN2 exons. Arrows within boxes display orientation relative
to transcription start. Green stars show approximate location of loxP sites (lox71, lox 66) in SmnRes. Black lines connecting exons show splicing pattern
for the predominant transcript encoded by each allele. Protein products are named to the right. SMN67m8h is the transcript encoded by the repaired
SmnRes allele. Not drawn to scale.
doi:10.1371/journal.pone.0075866.g001
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Materials and Methods
Ethics Statement
Care and treatments of all animals followed the National
Institutes of Health Guide for the Care and Use of Laboratory
Animals, and were approved by the Institutional Animal Care and
Use Committee (IACUC) of Texas A&M University under animal
use protocol 2010-0258.
Mice
Mice were housed in a vivarium at 25uC with a 12 h light/dark
cycle, fed ad libitum and monitored daily for health. Human alleles
are referred in the text with the standard convention of capital
letters in italics. SmnRes carriers (SmnRes/+; SMND7+/+; SMN2+/+,
JAX stock #007951) and Hb9Cre carriers (Hb9Cre+/2; Smn+/2;
SMND7+/+; SMN2+/+, JAX stock # 007022) were initially
acquired from the Jackson Labs, Bar Harbor, ME. The Hb9Cre
allele in 007022 came from JAX stock# 006600, the same Hb9-
Cre line used by DiDonato and colleagues to rescue Smn2B-Neo/2B-Neo
mice [14], and that has been used by others in many developmental
studies of motor neurons (e.g. [22,23]). These lines were bred in our
facility to generate Hb9Cre+/2; SmnRes/+; SMND7+/+; SMN2+/+ mice.
For experiments, the latter were bred to SmnRes carriers. The
genotype for the rescued animals, designated as Hb9(Cre+)SMA,
was Hb9Cre+/2; SmnRes/Res; SMND7+/+; SMN2+/+. The genotype for
the disease animals, designated as Hb9(Cre2)SMA, was Hb9Cre2/2;
SmnRes/Res; SMND7+/+; SMN2+/+. Controls were SmnRes/+ or Smn+/+
mice derived from the same crosses.
The initial design of the study assumed that precise measures of
lifespan, from birth until death, were essential to determine the
effects of the selective raising of SMN in motor neurons of SMA
mice. Thus, the approved animal use protocol for this study
allowed death without euthanasia as an endpoint for the survival
analysis. This accommodation turned out to be critical as the
results showed that our experimental manipulation had no effect
on survival. Had the differences in lifespan been more clear
between our rescued and diseased animals, it would have been
possible for us to establish a set of symptoms and criteria that
would have allowed euthanasia before death without fear of
changing or affecting the final results of the survival analysis. To
minimize the number of SMA mice used in the study, animals that
were followed for survival analysis were also used for longitudinal
studies of weight progression and righting reflex. A separate set of
control and SMA mice were used later to perform the hindlimb
suspension test. This experiment was terminated at postnatal day
(P) 12, before the SMA animals reached their mean lifespan of
,14 days. NMJ phenotypes were analyzed in P9-P11 animals.
Detailed descriptions of methods for all these experiments are
provided below.
Genotyping
Upon either death or weaning of the experimental progeny,
tissue samples were obtained from tail, spinal cord, skeletal muscle,
kidney, brain, heart and stomach. DNA was extracted and
amplified by PCR using REDExtract-N-Amp Hot start according
to manufacturer instructions (Sigma-Aldrich, St. Louis, MO).
Primers: Cre was detected using the custom primers: Forward: 59-
CATTTGGGCCAGCTAAACAT-39, Reverse: 59-CCCGGCA-
AAACAGGTAGTTA-39. The product was 454 bp. Smn2 was
detected with the following custom primers: Forward: 59-
CTTGGGTGGAGAGGCTATTC-39, Reverse: 59-AGGTGA-
GATGACAGGAGATC-39. Smn+ was detected with primers
oIMR7033 and oIMR7034 (Jackson labs, Bar Harbor, ME).
SMN2 was detected with primers oIMR5065, oIMR5066,
oIMR5067 (Jackson labs, Bar Harbor ME).
Quantitative-real time-polymerase chain reaction (qRT-
PCR)
Total RNA was extracted from P4 whole spinal cords and
hindlimb skeletal muscle using Trizol reagent according to
manufacturer instructions (Life Technologies, Grand Island, NY)
and stored at -80uC until use. 1 mg of RNA per sample was reverse
transcribed to cDNA using the High Capacity cDNA reverse
transcription kit according to manufacturer instructions (Life
Technologies, Grand Island, NY). Quantitative-RT-PCR for full
length SMN transcripts encoded by the recombined SmnRes allele
(SMN67m8h, Fig 1) was performed as described previously by
Martinez et al. [13]. The 18S rRNA primers and probe were from
Life Technologies, Grand Island, NY. Samples were set up in
triplicate using a TaqmanHMaster mix (Life Technologies, Grand
Island, NY) and run for 48 cycles in an ABI Prism 7900HT Fast
Real-Time PCR System (Life Technologies, Grand Island, NY).
The DDCt method [24] was used to determine changes in mRNA
transcript expression levels between groups.
Survival analysis
Our experimental litters were monitored twice daily for
potential mortalities. As soon as death of an animal occurred,
lifespan was recorded and samples of the above-mentioned tissues
were taken for genotyping. All animals assayed (n= 187) were
grouped according to genotype and lifespan (days). Survival data
was plotted on Kaplan-Meier survival curves using Prism5
(GraphPad Software, La Jolla, CA).
Weight progression
On P3, pups were tattooed with Indian black ink for
identification purposes and henceforth weighed every three days
to determine weight changes over the time course of 21 days (until
weaning for controls and death for mutants). All animals assayed
(n= 150) were grouped according to genotype and mean weights
for each time point were plotted using Prism5 (GraphPad
Software, La Jolla, CA).
Motor function
A righting reflex test was performed every three days on the
same animals used for weight progression above. The test
consisted of placing the pup in supine position on a flat surface
and measuring the time it took to turn over onto an upright
position, or to ‘‘right’’ itself, by having all four paws simultaneously
on the flat surface. This measurement was taken in duplicate and
averaged. All animals assayed (n= 150) were grouped according to
genotype and mean time to ‘‘right’’ for each time point was scored
according to the following scale, modeled after Monani and co-
workers [10]: 024 s = 5, 529 s = 4, 10214 s = 3, 15220 s = 2,
21249 s = 1, 502.60 s = 0. A score of 0 was considered a failed
test. Scores were plotted using Prism5 (GraphPad Software, La
Jolla, CA). The hindlimb suspension (tube) test was performed as
described by El-Khodor and colleagues [25]. Only latency time to
fall (up to 60 s) was considered in the analysis.
Neurofilament (NF) accumulation assay
NMJ staining was performed on whole mounts of P10-P11
tibialis anterior (TA) muscle. Pups were sacrificed with CO2,
muscles were dissected, fixed in 4% paraformaldehyde (PFA) for
,2 h at room temperature and washed extensively in PBS. To
facilitate antibody penetration, forceps were used to break muscle
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into bundles that remained attached to one tendon. Such muscles
were then permeabilized in methanol for 5 min at 220uC, and
washed in PBS. Muscles were blocked for 1 h in PBS+0.2% BSA,
0.3% Triton X-100. To label NF’s, samples were incubated
overnight at room temperature on a rocker with 2H3 monoclonal
antibody (1:100, Developmental Studies Hybridoma Bank, Iowa
City, IA). The following day, muscles were washed three times in
PBS-T (PBS+0.1% Triton X-100) and then incubated for 2 h in
rhodamine goat anti-mouse secondary antibody (1:200, Jackson
Immunoresearch, West Grove, PA) and fluorescein-conjugated a-
bungarotoxin (BTX) (1:1000, Life Technologies, Grand Island,
NY) to label acetylcholine receptors (AChRs). After washing
samples three times in PBS-T, muscle bundles were separated and
mounted on microscope slides using VectaShield (Vector Labo-
ratories, Burlingame, CA). Slides were observed under an
epifluorescence microscope fitted with a Z-motorized stage (Nikon
Eclipse E1000, Nikon, Tokyo, Japan) with a 100X, 1.3 NA oil
objective. Images of NMJs were taken with a CoolSNAP fx CCD
camera (Photometrics, Tucson, AZ) and captured with Meta-
Morph (Molecular Devices, Downingtown, PA). An observer,
blind to genotype, initially classified NMJs as either NF
accumulation positive (diseased) or negative (normal). NMJs were
later grouped according to genotype for quantitative analysis.
Innervation status
P9 triceps muscles were dissected, fixed in 4% PFA for 24 h and
cryoprotected in sucrose at 4uC for another 24 h. Muscles were
sliced in a cryostat into 40 mm longitudinal sections. Free-floating
sections were blocked in PBS+10% normal goat serum for 1 h at
room temperature. Sections were later incubated overnight in
either an antibody to synaptophysin (1:300, Life Technologies,
Grand Island, NY) or in a 2H3 monoclonal antibody (1:100,
Developmental Studies Hybridoma Bank, Iowa City, IA). The
following day all sections were washed in PBS-T and incubated for
2 h either in rhodamine goat anti-rabbit antibody (1:1000, Jackson
Immunoresearch, West Grove, PA) or in rhodamine goat anti-
mouse secondary antibody (1:200, Jackson Immunoresearch, West
Grove, PA) respectively. Fluorescein-conjugated a-bungarotoxin
(BTX) (1:1000, Life Technologies, Grand Island, NY) was added
to label acetylcholine receptors (AChRs). After washes in PBS-T,
all free-floating sections were mounted on slides using VectaShield.
A 40X, 1.3 NA oil objective was used to acquire wide field images
of NMJs with MetaMorph Software. Endplates stained with
synaptophysin were assessed blind to genotype for their innerva-
tion status by qualitatively classifying each junction into either
fully-occupied (.75%), partially-occupied (25–75%) and unoccu-
pied (,25%) depending on the relative proportion of synapto-
physin staining versus the overall area of the AChR staining. NMJs
stained for NF and BTX were assessed for status of innervation by
categorizing them as innervated if there was any overlap between
the two stains or denervated if NF was completely absent at the
synaptic site.
Endplate size
AChR area was calculated from the images of P9 TA whole
mounts and from P9 triceps longitudinal sections using the
MetaMorph software.
Myofiber area and diameter
P9 TA muscles were dissected and flash frozen with OCT
medium (tissue tek) in an isopentane/liquid N2 bath. 14 mm-thick
cross-sections were cut in a cryostat and mounted on a slide.
Sections were fixed in 1% PFA for 10 min and then washed three
times in PBS-T for 5 min each. The cross sections were blocked in
PBS+10% normal goat serum for 20 min at room temperature
and then incubated overnight in a dystrophin antibody (1:300,
Abcam, Cambridge, MA). After three 15 min washes in PBS-T
the following morning, the muscle sections were incubated at
room temperature for 2 h with a fluorescein-conjugated goat anti-
rabbit secondary antibody. After washes in PBS-T, slides were
mounted using VectaShield. A 20X, 0.5 NA oil objective (Nikon)
was used to acquire wide field images of myofibers with
MetaMorph Software, taking as many images needed to
encompass the entire area of a single whole muscle section
avoiding overlapping myofibers. The dystrophin stained images
were analyzed for myofiber area and diameter by first thresholding
the calibrated image for dark objects and manually adjusting said
threshold to fill the entire interior core surrounded by dystrophin
staining of as many myofibers as possible per image. Next regions
were drawn automatically around each individual fiber, and lastly
the integrated morphometric analysis tool in MetaMorph was used
to determine area and breath, which is the caliper width of the
object perpendicular to the longest chord. This approach allows
simultaneous accurate determination of myofiber size parameters
in a large number of fibers. It is quicker than the traditional
approach of measuring these parameters in single fibers at a time.
Statistical analysis
Quantitative data are expressed as mean 6 SEM. Values for
number of animals and NMJs analyzed are given in the figure
legends. Kaplan-Meier survival curves were generated and tested
for statistical significance using the log-rank test with Prism5
GraphPad Software. Analysis of the Variance (ANOVA) was used
to check for significance in weight and motor function data using
SAS software (SAS Institute, Cary, NC). Student’s t-test,
computed either with Microsoft Excel (Microsoft Corporation,
Seattle, WA) or Prism5 GraphPad Software, was used to probe for
statistical significance in NF accumulation, innervation status and
endplate size data. Significance was set at p#0.05.
Results
Spinal cord-specific recombination of the SmnRes allele
The hybrid SmnRes allele has an inverted (i.e. 39R59),
translationally silent mouse Smn exon 7 in the intron between
human SMN2 exon 7 and 8 (Fig 1). Mutant (lox71/lox66) loxP sites
in opposite orientation were engineered upstream of SMN2 exon 7
and downstream of the inverted Smn exon 7, respectively. In this
form, this allele potentially codes for transcripts containing Smn
exons 1–6 and SMN2 exons 7 and 8. However, it was found that in
this configuration SmnRes fails to encode transcripts for full-length
SMN and only produces transcripts lacking SMN2 exon 7 that
code for SMND7 protein (Fig 1). Hence SmnRes is functionally a
null Smn allele [11]. Upon Cre recombination, Smn exon 7 59R39
orientation is irreversibly restored so that transcripts containing
Smn exons 1–7 and SMN2 exon 8 (SMN67m8h) are generated,
which encode full length SMN (Fig 1). SmnRes/Res mice are
embryonic lethal, however, when SmnRes replaces the Smn null
allele in an SMAD7 background, the resulting SmnRes/Res mice
display essentially the same SMA phenotype as standard SMAD7
mice [11]. Thus, these mice are ‘‘conditional’’ SMAD7 mice.
Repairing the SmnRes allele using Cre-lines that express the
recombinase ubiquitously from early development rescued the
normal phenotype of the mice, validating the recombined, hybrid
SmnRes allele as a WT-surrogate Smn allele [11].
To restore SMN expression selectively in motor neurons, we
sought to drive the repair of the SmnRes allele with Hb9-Cre. The
homeobox gene Hb9 is selectively expressed in spinal cord somatic
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and visceral motor neurons and Vx interneurons starting at
embryonic (E) day 9.5 [26,27]. In the Hb9Cre allele an IRES-Cre
cassette was knocked-in into the first exon of the Hb9 gene. Thus,
Cre expression under Hb9 control follows the expression pattern of
endogenous Hb9. Hb9Cre is homozygous lethal thus only hetero-
zygous animals survive past birth. The experimental crosses
consisted of SmnRes carriers (SmnRes/+; SMND7+/+; SMN2+/+, JAX
stock #007951) bred to Hb9Cre+/2; SmnRes/+; SMND7+/+; SMN2+/+
mice. The genotype for the rescued animals, designated as
Hb9(Cre+)SMA, was Hb9Cre+/2; SmnRes/Res; SMND7+/+; SMN2+/+.
The genotype for the disease animals, designated as
Hb9(Cre2)SMA, was Hb9Cre2/2; SmnRes/Res; SMND7+/+; SMN2+/+.
Controls were SmnRes/+ or Smn+/+ mice derived from the same
crosses. Their precise genotypes were: Hb9Cre?/2; SmnRes/+;
SMND7+/+; SMN2+/+ and Hb9Cre?/2; Smn+/+; SMND7+/+; SMN2+/+.
Genomic PCR confirmed spinal cord-selective, Hb9Cre driven
recombination of SmnRes in our Hb9(Cre+)SMA mice as the
repaired allele was only detected in spinal cord, but not in skeletal
muscle, kidney (Fig 2A), brain, heart or stomach (data not shown).
Comparison between Hb9Cre and ChATCre driven repair of
the SmnRes allele
We used quantitative RT-PCR to measure the levels of the
recombined, repaired transcript SMN67m8h, which encodes full-
length SMN (Fig 1), in P4 spinal cord and muscle. We chose this
early time point because disease symptoms were not overt at this
stage. We followed the same methodology described by Martinez
and colleagues and used as controls P4 spinal cord and muscle
tissue from their ChATCre+ and Myf5Cre+ conditional SMAD7 mice
[13]. Primers were designed to recognize the SMN67m8h
transcript. The forward primer cut across Smn exons 6 and 7
exon/intron boundary and the reverse primer bound to SMN2
exon 8 ([13]; Fig.1). Cycle threshold (Ct) values obtained for 18S
rRNA were used to equalize differences in total RNA per sample.
Transcript level fold change was determined by the 2-DeltaDeltaCt
method [24] and values were normalized to the Ct values obtained
for ChATCre+; SmnRes/Res spinal cord samples. In our hands, relative
SMN67m8h expression levels for ChATCre+; SmnRes/Res and Myf5Cre+;
SmnRes/Res samples were very similar to those reported before [13]
(Fig 2B). In fact, the Ct values obtained with these samples were
almost identical to the Ct values obtained previously with other
samples with the same genotypes [13]. However, P4 Hb9Cre+;
SmnRes/Res spinal cord had approximately 100-fold lower levels of
SMN67m8h transcript than ChATCre+; SmnRes/Res spinal cord
(Fig 2B). Consistent with our prior results at the genomic level
(Fig 2A), SMN67m8h transcript was undetectable in muscle
samples from either Hb9Cre+; SmnRes/Res or Hb9Cre-; SmnRes/Res mice
(data not shown). Nor was SMN67m8h detected in spinal cord from
Hb9Cre-; SmnRes/Res animals (data not shown). Thus, although these
results confirm at the mRNA level the spinal cord specific
recombination driven by Hb9Cre in conditional SMAD7 mice, they
unexpectedly show that full length SMN expression in these mice
is remarkably much lower than in ChATCre+ conditional SMAD7
mice.
We failed to detect an increase in SMN protein levels by
Western blot in spinal cord from Hb9Cre+; SmnRes/Res animals
relative to spinal cord from Hb9Cre-; SmnRes/Res mice (data not
shown). This is not surprising in light of the fact that this increase
was not even observed when ChATCre drove the repair of SmnRes in
conditional SMAD7 mice, which is probably due to the small
proportion of motor neuron-derived material in lysates from whole
spinal cord.
Survival, weight progression and motor behavior in
Hb9(Cre+)SMA mice
Having obtained evidence of spinal cord-selective recombina-
tion and expression, we next characterized the phenotype of
Hb9(Cre+)SMA mice. Median survival for Hb9(Cre2)SMA mice
was 14.662.64 days (n = 20) (Fig 3A). This value agrees very well
with the mean survival reported by others for these mice [11,13]
and for the original SMAD7 animals [4], which suggests that our
breeding strategy did not alter the basic phenotype of the mice.
Hb9(Cre+)SMA mice displayed a statistically similar lifespan
(Fig 3A; 13.4163.73 days, n = 37, p = 0.6436, log-rank test). Both
SMA lines were clearly unable to gain the weight that controls did
(Fig 3B). Hb9Cre+ and Hb9Cre- conditional SMAD7 mice gained
some weight between P3 and P9, but it declined steadily
henceforth until time of death (Fig 3B). Hb9(Cre+)SMA mice
tended to be a little heavier than Hb9(Cre2)SMA mice between
P9 and P18, but this difference was statistically significant by
ANOVA only at P12 (F = 9.78; p = 0.004). Motor behavior was
assessed using the righting reflex and the hindlimb suspension tests
(Fig 3C and 3D). As expected heterozygous and WT controls
performed much better than SMA mice in these tests. No
statistical differences in motor function were apparent between
Hb9(Cre+)SMA and Hb9(Cre2)SMA mice. Thus we failed to
detect improvements in lifespan and motor behavior in
Hb9(Cre+)SMA animals, even though there was a slight tendency
for increased weight.
Neuromuscular phenotypes in Hb9(Cre+)SMA mice
While Hb9-Cre-driven rescue of conditional SMAD7 mice had
no apparent effect at the whole animal level, it was still possible
that their NMJ pathology could be rescued by this approach.
Accumulations of neurofilament (NF) staining at the nerve
terminal are a hallmark pathological feature in SMA mice
[5,6,8,28], and they were reduced to control levels in ChATCre+
conditional SMAD7 mice [13]. We stained whole mount
preparations from P10 tibialis anterior (TA) muscle for NF and
AChRs to mark NMJs. While about 10% of endplates had pre-
synaptic NF accumulations in controls, over 80% of NMJs
displayed them in Hb9Cre+ or Hb9Cre- conditional SMAD7
preparations (Fig 4). Thus, NF accumulations in nerve terminals
persisted in Hb9(Cre+)SMA mice.
Endplate size in TA muscle, as measured by the area occupied
by AChRs, was one of the synaptic phenotypes rescued in
ChATCre+ conditional SMAD7 mice [13]. We determined AChR
area in whole mount TA preparations and in longitudinal sections
of triceps muscles from P9 animals. To capture many NMJs per
image and to ensure imagining of the entire junctional surface,
wide field 3D images of the BTX-stained tissue were taken with an
epifluorescence microscope fitted with a motorized Z-axis. Using
Methamorph software, the Z-stacks were first flattened to the X/Y
dimensions and endplate area was determined after thresholding
of images. The average TA endplate areas for control
(185.1066.87 mm2) and Hb9(Cre2)SMA (11560.94 mm2) geno-
types were very similar to those reported previously for P9 TAs in
control and SMAD7 mice, respectively, which were imaged by
confocal microscopy [6]. In Hb9(Cre+)SMA mice average TA
endplate area was 170.1167.08 mm2. Figure 5A,B shows that
endplate area for both TA and triceps NMJs was restored to
control values in Hb9(Cre+)SMA mice. Thus, appendicular
muscles innervated by pools of motor neurons in opposite ends
of the spinal cord, cervical (triceps), lumbar/sacral (TA), had their
average endplate area rescued in Hb9(Cre+)SMA mice. In normal
animals endplate size correlates with myofiber size [29]. Following
labeling of transverse sections for dystrophin to mark cell surface,
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we determined mean myofiber area and diameter in TA muscles
from P9 controls, Hb9(Cre+) and Hb9(Cre2)SMA mice. We
focused on this muscle because it was used previously by Martinez
et al [13] in their analysis of these parameters in ChATCre-, Myf5Cre-
and MyoDiCre- SMAD7 mice. Dystrophin staining was qualitatively
similar between genotypes (Fig 5C). As expected, mean myofiber
area and diameter were larger in controls than in SMA mice and
were within the range reported previously [6,13]. However, there
were no differences in these parameters between Hb9(Cre+) and
Hb9(Cre2)SMA mice (Fig 5D,E) (Control, area = 449.46
44.94 mm2; diameter = 22.0761.08 mm. Hb9(Cre+)SMA, area=
297.06611.10 mm2; diameter= 17.5360.37 mm. Hb9(Cre2)SMA,
area= 268.05632.49 mm2; diameter = 16.9660.86 mm). Thus, the
increase in endplate size in the TA muscle from Hb9(Cre+)SMA
mice was observed in the absence of a corresponding increase in
myofiber area and diameter.
Ko and colleagues demonstrated a selective vulnerability to
denervation of specific, clinically relevant muscles in SMAD7 mice
[9]. Denervation of vulnerable muscles was restored to control
values in ChATCre+ conditional SMAD7 mice [13]. We determined
the innervation status of NMJs in the triceps, one of the reported
vulnerable appendicular muscles [9], by first co-staining longitu-
dinal sections for AChRs and synaptophysin, a synaptic vesicle
marker. While lack of synaptophysin staining may not be
indicative of structural denervation (i.e. absence of an axon
terminal), increased synaptophysin coverage of an endplate is
necessarily associated with axon terminal presence. Images were
taken and processed as above. Endplates were classified as fully-
occupied if at least ,75% of the AChR area was covered by
synaptophysin staining. On the other hand, they were deemed as
unoccupied if less than ,25% of the AChR area showed
synaptophysin staining. Endplates with synaptophysin staining in
between were categorized as partially occupied. We found a
statistically significant improvement in the synaptophysin coverage
of the P9 triceps endplates in Hb9(Cre+)SMA mice (Fig 6B). Thus,
the fraction of fully-occupied synapses increased in Hb9Cre+
Figure 2. A. Spinal cord-specific Cre recombination of the SmnRes in Hb9(Cre+)SMA mice. Genomic DNA was prepared from spinal cord
(SpC), skeletal muscle (SkM), and kidney (K) from 2 Hb9Cre+ and 2 Hb9Cre2 SMA animals postmortem. All animals died within the first two postnatal
weeks suggesting they were SmnRes/Res. Top panels: Genomic PCR specific for the inverted, recombined SmnRes allele demonstrated its presence only
in the spinal cord samples and not in the skeletal muscle or kidney samples. All these samples were positive for SMN2, which showed DNA integrity.
Sizes of the expected DNA bands are indicated to the left of each panel. M: 100 bp ladder. (+): positive controls. Spleen DNA from a germline inverted
SmnRes/Res animal was used as positive control for the recombined allele PCR. B. Relative SMN67m8h expression in Hb9Cre, ChATCre and Myf5Cre
SMA lines at P4. The ordinate, in log scale, shows SMN67m8h expression normalized to levels in ChATCre SMA spinal cord. Hb9Cre SMA spinal cord
displayed ,100-fold lower expression than ChATCre SMA spinal cord. N= 2–4, per genotype.
doi:10.1371/journal.pone.0075866.g002
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SMAD7 mice over that in SMA mice
[Hb9(Cre+)SMA=57.4765.58%; Hb9(Cre2)SMA=23.0061.65%],
while the fraction of unoccupied endplates decreased in the rescued
animals relative to SMA mice [Hb9(Cre+)SMA=25.9766.2%;
Hb9(Cre2)SMA=48.9363.37%]. Partially-occupied synapses also
were reduced in numbers in Hb9(Cre+)SMA mice [15.2960.86%
vs. 29.4662.11% in Hb9(Cre2)SMA animals]. However, the
improvement in synaptophysin occupancy in the Hb9Cre+ SMAD7
mice did not quite reach the levels observed in the control animals
(Fig 6B). To directly assess structural innervation, we co-stained serial
triceps longitudinal sections for AChRs and neurofilament, a structural
axonal marker. Synaptic sites labeled with BTX were considered
innervated if there was overlap, however small, between NF and
AChR staining, while complete lack of NF at synaptic sites categorized
them as denervated (Fig 6C). Innervation was also improved clearly in
Hb9(Cre+)SMA triceps using overlap between NF and BTX as scoring
criterion (Fig 6D). Thus, Hb9(Cre2)SMA triceps had 56.2961.11% of
innervated endplates, whereas Hb9(Cre+)SMA triceps displayed
86.3662.6% innervated synapses, a percentage similar to controls.
Thus, of the three NMJ structural phenotypes examined,
endplate area and innervation status, but not presynaptic NF
accumulation, showed significant improvements in
Hb9(Cre+)SMA mice relative to diseased animals. Interestingly
the increase in endplate size appeared to occur in the absence of
an increase in myofiber size.
Discussion
Compared to previous studies [13,14,30] ours seems to be the
one in which restored spinal cord SMN levels are the lowest. Yet
we were able to document full rescue of endplate size regardless of
the susceptibility of a muscle to denervation and substantial
recovery of innervation on a denervation vulnerable muscle. The
increase in endplate size was not the result of an increase in muscle
fiber size. The implication for therapeutics evaluation of this
observation is that rescue of endplate size could be interpreted as a
direct benefit on motor neurons rather than an indirect result of an
increase in muscle fiber girth. Hence, our experiments uniquely
highlight the exquisite sensitivity of these NMJ phenotypes to very
small changes in SMN in spinal cords. These two phenotypes can
be rescued by SMN levels that fail at reducing presynaptic NF
accumulation, increasing animal weight and lifespan or improving
overall motor performance. All of the above phenotypes were
rescued or improved in ChATCre+ conditional SMAD7 mice [13],
which our data suggest display substantially more efficient Cre-
mediated recombination in spinal cord than Hb9Cre+ conditional
SMAD7 mice. Despite the inefficient restoration of motoneuronal
SMN in Hb9Cre+ conditional SMAD7 mice, the subclinical
neuromuscular innervation improvements that can be measured
Figure 3. Hb9-Cre recombination fails to improve lifespan,
weight gain and motor behavior in SMAD7 mice. A. Kaplan-Meier
curves demonstrate no increase in survival, p = 0.6436, log-rank test.
Mean life span: Hb9(Cre+)SMA: 13.4163.73 days, n = 37. Hb9(Cre2)SMA
mice: 14.662.64 days; n = 20. Controls: n = 130. B. While controls
(n = 107) gained weight as expected, no statistical differences in weight
were found during the lifespan of Hb9(Cre+)SMA and Hb9(Cre2)SMA
mice except at P12 (*p= 0.004, F = 9.78, ANOVA). Hb9(Cre+)SMA: n = 10–
27 per time point. Hb9(Cre2)SMA: n= 3–16 per time point. C and D.
Motor behavior was assessed by the righting reflex (C) and hindlimb
(tube) suspension (D) tests. Only the latency to fall was recorded for the
tube assays. While controls improved their performance with age, SMA
mice motor behavior deteriorated as they approached end stage. For
the righting reflex assays: Controls: n = 107 per time point.
Hb9(Cre+)SMA: n = 7–27 per time point. Hb9(Cre2)SMA: n = 4–16 per
time point. For the tube test: Controls: n = 148 per time point.
Hb9(Cre+)SMA: n = 7–28 per time point. Hb9(Cre2)SMA: n = 5–17 per
time point.
doi:10.1371/journal.pone.0075866.g003
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Figure 4. Neurofilament (NF) accumulation at nerve terminals fails to be rescued in Hb9(Cre+) SMA mice. Whole mounts of P10 TA
muscle stained for components of the NMJ. A. Representative images for each of the 3 genotypes assayed. Protuberances or ‘‘blebbing’’ of the nerve
terminals (arrowheads) are distinct evidence of SMA pathology. Green: NF, Red: BTX. Scale bars: 20 mm. B. Quantification of NF accumulation as seen
in A. The ordinate plots the mean percentage of NMJs with NF accumulation per genotype. Most NMJs in Hb9(Cre+) and Hb9(Cre2) SMA mice had NF
accumulations, while only a minority of endplates in controls showed so. Controls n = 9 animals, 107 NMJs. Hb9(Cre+)SMA n=4 animals, 52 NMJs.
Hb9(Cre2)SMA n=3 animals, 95 NMJs.
doi:10.1371/journal.pone.0075866.g004
Figure 5. Endplate size is rescued in Hb9(Cre+) SMA mice without change in myofiber size. A. and B. Quantification of endplate size in
P9 TA and triceps muscles, respectively. TA endplate size was determined in whole-mount preparations. Triceps endplate area was determined in
longitudinal sections from images such as that displayed in Fig 6A. Endplate area was rescued in both muscles in Hb9(Cre+)SMA mice. TA: Controls:
n = 5 animals, 512 NMJs. Hb9(Cre+)SMA n=3 animals, 465 NMJs. Hb9(Cre2)SMA n=3 animals, 303 NMJs. Triceps: Controls n = 5 animals, 505
endplates. Hb9(Cre+)SMA n= 3 animals, 524 endplates. Hb9(Cre2)SMA n= 3 animals, 316 endplates. **p=0.002. *p = 0.008 (t-test). C. Representative
images of dystrophin stain for 14- mm-thick transverse sections of control and SMA P9 TA muscles. Dystrophin staining is qualitatively similar
between genotypes but differences in fiber caliber between control and SMA muscles are evident. Scale bars: 50 mm. D. and E. Quantification of
mean myofiber area and diameter of P9 TA muscles, respectively. Controls: n = 2 animals, 3116 fibers. Hb9(Cre+)SMA n= 3 animals, 5729 fibers.
Hb9(Cre2)SMA n=3 animals, 4511 fibers.
doi:10.1371/journal.pone.0075866.g005
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in them raise the possibility that similar benefits could be seen in
SMA patients even when the latter are under therapeutic
interventions with known modest effects in raising SMN levels.
The pattern of structural neuromuscular phenotypes rescued in
Hb9Cre+ conditional SMAD7 mice was very similar to that in
Myf5Cre+ conditional SMAD7 mice. Thus, TA endplate size and
innervation status of a vulnerable muscle (the splenius capitis), but
not levels of NF accumulation, were rescued in Myf5Cre+
conditional SMAD7 mice. Myf5Cre+ is strongly expressed in skeletal
muscle but also weakly in spinal cord, including motor neurons
(Fig 2B, [13]). Although whole spinal cord samples from Myf5Cre+
and ChATCre+ conditional SMAD7 mice seemed to have similar
SMN67m8h levels (Fig 2B, [13]), it is important to point out that
only a fraction of the full-length SMN expression in Myf5Cre+
conditional SMAD7 mice may come from motor neurons
themselves as Myf5Cre+ was found strongly expressed in ChAT-
negative ventral horn neurons and in dorsal root ganglia [13].
Thus, it is possible that expression of Myf5Cre+ and Hb9Cre+ in
motor neurons may be more similar than suggested by our
qRT-PCR in whole spinal cord samples. Our results with Hb9Cre+
SMA mice strongly suggest that the rescue of endplate size and
innervation status in Myf5Cre+ SMA mice is explained by its
expression in motor neurons and not in muscle. This is consistent
with the observation that these phenotypes were not rescued in
MyoDiCre+-expressing animals, which only had Cre expression in
muscle but not spinal cord [13]. In normal animals, there is a
direct correlation between muscle fiber girth and endplate size
[29]. However, TA fiber diameter increased in MyoDiCre+-
expressing animals without a corresponding increase in endplate
size [13] and the increase in P9 TA endplate size observed here
occurred without a change in average muscle fiber size (Fig 5C-E).
Thus, together these data suggest that endplate size, at least in
SMA severe mice, is largely a motor neuron cell autonomous
phenotype. While structural NMJ phenotypes, excluding NF
accumulation, were improved in Hb9Cre+- and Myf5Cre+-conditional
SMAD7 mice (this work and [13]), central structural phenotypes
(i.e. loss of motor neuron numbers and of glutamatergic synapses
onto their somas), which we did not analyze here, were not rescued
Figure 6. Innervation status is improved in Hb9(Cre+) SMA mice. A. A longitudinal section (40 mm-thick) from triceps muscle, from a P9
Hb9(Cre+)SMA animal, co-stained for synaptophysin (SYN) and BTX, to label nerve terminals and AChRs, respectively. A flattened 2D image derived
from a wide field 3D stack for the fluorescein (AChR) and rhodamine (SYN) channels and their merge is shown. Two NMJs in the upper left have
complete coverage of SYN staining over AChR staining, and are examples of fully-occupied (FO) NMJs. Two endplates in the bottom right (arrow), one
sideways, one en face, lack detectable SYN staining, and are examples of unoccupied (U) endplates. The one endplate in the middle is partly covered
by SYN staining and is an example of a partially-occupied (PO) NMJ. Scale bar: 20 mm. B. Quantification of synaptophysin occupancy of triceps
endplates. The percentage of fully-occupied NMJs was increased, and the percentage of partially- and unoccupied endplates were reduced in
Hb9(Cre+)SMA mice relative to Hb9(Cre2)SMA animals (*p,0.008, t-test). Controls: n = 5 animals, 403 endplates. Hb9(Cre+)SMA: 3 animals, 394
endplates. Hb9(Cre2)SMA: 3 animals, 439 endplates C. Top panels: Representative merged images of P9 triceps longitudinal sections stained for NF
(red) and BTX (green). Bottom panels: NF channel in black & white. In the top left panel (control) axons can be seen overlapping part of the BTX stain
or barely entering the synaptic site (endplate on the lower right corner). Arrowheads in the middle panels indicate NF accumulations at synaptic sites
on Hb9(Cre+) SMA tissue. All the synapses in the middle panels were considered as innervated, three of them are indicated as (I). The right top panel
(Hb9 (Cre2) SMA) shows two examples of endplates completely lacking NF/BTX overlap and thus considered denervated (D). These two endplates
have been outlined in green in the bottom right panel, to further clarify their lack of overlapping NF staining. Scale bars: 50 mm. D. Quantification of
triceps innervation using NF/BTX overlap as criterion. The percentage of innervated endplates was increased and the percentage of denervated NMJs
were reduced to control levels in Hb9(Cre+)SMA mice relative to Hb9(Cre2)SMA animals (*p = 0.0004, t-test). Controls: n = 3 animals, 533 endplates.
Hb9(Cre+)SMA: 3 animals, 478 endplates. Hb9(Cre2)SMA: 3 animals, 559 endplates.
doi:10.1371/journal.pone.0075866.g006
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in Myf5Cre+-expressing animals [13]. They were mitigated in the
higher SMN expressing ChATCre+ conditional SMAD7 mice [13].
Together the above results suggest that peripheral structural
phenotypes may be more sensitive to levels of SMN than central
structural phenotypes.
The expression patterns for ChAT and Hb9 largely overlap in
that they both are present in motor neurons. Hb9 may come up
earlier during development than ChAT, but it is not surprising that
the latter drives higher levels of transcription than the former, as
transcription factor genes are generally expressed at lower level
than other genes. Sets of non-overlapping interneurons in the
spinal cord also express Hb9 and ChAT. The former is expressed in
glutamatergic Vx interneurons, while the latter is expressed in
cholinergic V0c interneurons [27]. V0c interneurons are marked
by expression of the Pitx2 transcription factor and interestingly
modulate motor output amplitude [31]. It is a remote, though
testable, possibility that restoration of SMN expression in V0c
interneurons in ChATCre+ conditional SMAD7 mice contributes to
the difference between our results and those of Martinez and
colleagues [13]. Much more likely is the possibility that
recombination of the SmnRes allele is more efficiently driven by
ChATCre than by Hb9Cre simply because higher levels of the
recombinase result from the former than the latter. Thus, one
possibility is that recombination fails in many more motor neurons
in Hb9(Cre+)SMA than in ChAT(Cre+) SMA mice. This may be
critical to mitigate whole animal phenotypes such as survival,
weight and motor function but not NMJ phenotypes such as
endplate size and innervation status as long as the endplates where
these phenotypes are examined are innervated by motor neurons
where Cre recombination occurred. Another possibility is that
both SmnRes alleles are repaired in more ChATCre-expressing than
Hb9Cre-expressing motor neurons. This would translate into higher
levels of SMN protein per motor neuron in ChATCre animals. Thus,
a combination of these non-exclusive alternatives may account for
the higher SMN67m8h transcript levels in spinal cord from
ChAT(Cre+)SMA mice, which lead to a more extensive rescue.
While our finding that spinal cord from Hb9Cre+ conditional
SMAD7 mice had remarkably much lower levels of full-length
SMN transcript than spinal cord from ChATCre+ conditional
SMAD7 mice explains our results vis-a`-vis those of Martinez and
colleagues [13], it is more difficult to account for the results of
Gogliotti and colleagues [14], who used the same Hb9Cre line we
used here, albeit to rescue a different conditional Smn allele (Smn2B-
Neo). To generate Smn2B-Neo, three nucleotide substitutions
(GGARTTT) were engineered in the exon splice enhancer within
Smn exon 7 and a pgk-neo cassette, flanked by WT loxP sites, was
inserted downstream in the intron between Smn exons 7 and 8
[12]. Upon Cre recombination, the pgk-neo cassette is excised, and
the allele becomes Smn2B [12,32]. Smn2B/2B mice show no signs of
SMA phenotype and have a normal lifespan, despite ,66%
decrease in SMN protein in spinal cord [32]. Contrary to SmnRes
[11], the Smn2B-Neo allele yields transcripts encoding full-length
SMN prior to Cre recombination (,7.5% WT allele levels [12]),
although like SMN2, the majority of its transcripts encode SMND7
[12]. Smn2B-Neo/2B-Neo mice are embryonic lethal that die between
E9.5-E12.5, later than Smn2/2 embryos, which die at E7.5 [12].
Full length SMN protein could be detected in Smn2B-Neo/2B-Neo
embryos at 1–3% WT levels, somehow lower than predicted by
the levels of transcript [12]. This embryonic lethality can be
rescued in Smn2B-Neo/2B-Neo; SMN2+/2 mice, which die perinatally
around P7 [14]. Like us, Gogliotti et al. used Hb9Cre to selectively
restore SMN in motor neurons of Smn2B-Neo/2B-Neo; SMN2+/2 mice
[14]. However, unlike results reported here with conditional
SMAD7 mice, they found improvements in lifespan (to just P12 on
average), weight, and motor behavior assayed by the righting
reflex and hindlimb suspension tests, the same tests used here.
NMJ pathology also improved in Hb9Cre+/2; Smn2B-Neo/2B-Neo;
SMN2+/2 mice. We propose that their more extensive rescue was
due to the endogenous low levels of full length SMN protein
afforded by the Smn2B-Neo allele, that together with those provided
by the Smn2B allele (i.e. after recombination) yielded higher overall
levels of SMN in motor neurons. This interpretation assumes that
the recombination efficiency of SmnRes and Smn2B-Neo was the same
in the two experiments as both used the same Hb9Cre line.
However, the recombination efficiency may not only depend on
the levels of Cre but also on the nature of the two conditional
alleles. Hence, to be repaired Smn2B-Neo requires the excision of the
pgk-neo cassette, while SmnRes requires the inversion of the 3959 Smn
exon 7 (Fig 1). The pgk-neo cassette in Smn2B-Neo is flanked by WT
loxP sites, while the inversion cassette in SmnRes is flanked by
mutant lox66/lox71 sites, which ensures the irreversibility of the
inversion reaction [33]. To reach comparable levels of recombi-
nation efficiency in vitro, Cre-mediated inversion of lox66/lox71-
flanked DNA regions requires 2–3 fold more Cre than Cre-
mediated excision of WT loxP-flanked DNA regions [33]. In vivo,
the same study showed that lox66/lox71 inversion was slightly less
efficient than WT loxP excision [33]. Thus, it is possible that the
Hb9Cre-driven recombination efficiency of Smn2B-Neo is higher than
that for SmnRes. This, together with the likely higher basal levels of
full-length SMN in Smn2B-Neo/2B-Neo; SMN2+/2 mice relative to
conditional SMAD7 mice, may account for the amelioration of less
SMN-sensitive phenotypes observed by Gogliotti et al. [14], which
we failed to observe in our experiments. Recent experiments by
others indicate that pathology in cells other than motor neurons
critically underlie the short lifespan of severe SMA mice (for
review see [34]). As the two lines carrying the inducible
conditional Smn alleles, SmnRes and Smn2B-Neo, continue to be used
to determine the contribution of other cell types to the SMA
phenotype and lifespan, it will be important that the research
community be aware of the differences between these two
conditional lines regarding their endogenous SMN levels and
their differential demand for Cre drivers. While used successfully
by many for excision of floxed alleles (e.g. references in http://
jaxmice.jax.org/strain/006600.html), our results raise the possi-
bility that Hb9Cre might not be a robust Cre driver for inversion of
floxed alleles in general.
Notwithstanding the involvement of other cell types suggested
by animal models, survival and other defects in motor neurons are
still expected to be hallmark features of the human disease. Having
biomarkers that directly reflect changes in motor neuron
phenotypes following a therapeutic approach is still very impor-
tant. The apparent higher SMN sensitivity and the easier
experimental accessibility of the NMJ better position peripheral
structural phenotypes to serve as biomarkers for testing therapeutic
interventions than central structural phenotypes. Indeed, Ko and
colleagues already demonstrated that denervation of vulnerable
muscles can serve as a very sensitive biomarker to evaluate
pharmacological interventions in SMAD7 mice [9]. Results of the
present study further support this conclusion. Our analysis of
endplate area in one denervation-vulnerable (triceps) and one
denervation-resistant (TA) muscle, innervated by motor neuron
pools located in opposite ends of the spinal cord, indicates that this
phenotype could also be used as a sensitive motor neuron-
autonomous marker to evaluate drug therapies in SMAD7 mice.
Although both parameters appear equally sensitive to small
increases in SMN levels, endplate size has the potential advantage
of applying to all muscles, regardless of their vulnerability to
denervation.
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